Publicação
Hyperkalemia management: a multidisciplinary expert panel’s perspective on the role of new potassium binders
| dc.contributor.author | Fonseca, Cândida | |
| dc.contributor.author | Garagarza, Cristina | |
| dc.contributor.author | Silva, Gil | |
| dc.contributor.author | Caires, Graça | |
| dc.contributor.author | Marques, Irene | |
| dc.contributor.author | Lopes, José António | |
| dc.contributor.author | Branco, Patrícia | |
| dc.contributor.author | Alves, Rui | |
| dc.contributor.author | Ferreira, Aníbal | |
| dc.date.accessioned | 2025-02-12T11:44:42Z | |
| dc.date.available | 2025-02-12T11:44:42Z | |
| dc.date.issued | 2024 | |
| dc.description | © The Author(s) 2024. This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. | pt_PT |
| dc.description.abstract | Hyperkalemia is a potentially life-threatening condition frequently encountered in clinical practice, particularly among patients with chronic kidney disease, heart failure, diabetes, and hypertension and those undergoing treatment with renin-angiotensin-aldosterone system inhibitors (RAASi). The management of chronic and acute hyperkalemia is complex and requires timely intervention to prevent severe complications such as cardiac arrhythmias and sudden death. Traditional therapeutic approaches to chronic hyperkalemia, including dietary potassium restriction, use of diuretics, and administration of cation-exchange resins like sodium polystyrene sulfonate, often suffer from limitations like gastrointestinal side effects, variable efficacy, delayed onset of action, and RAASi treatment discontinuation. In recent years, the development of new potassium binders, specifically patiromer and sodium zirconium cyclosilicate (SZC), has revolutionized the management of hyperkalemia. Patiromer, a non-absorbed polymer, binds potassium in the gastrointestinal tract in exchange for calcium, thus facilitating its excretion. SZC operates by exchanging sodium and hydrogen ions for potassium, leading to efficient potassium removal. Both agents have demonstrated rapid and sustained reductions in serum potassium levels, coupled with favorable safety and tolerability profiles, in multiple clinical trials. This review article, authored by a multidisciplinary group of Portuguese experts in hyperkalemia management, provides an in-depth analysis of the efficacy and safety of current therapeutic strategies and highlights the clinical potential of new potassium binders. The introduction of patiromer and SZC offers significant advantages over traditional therapies, providing effective and better-tolerated options for patients. The review highlights the role of these novel agents in contemporary hyperkalemia management and calls for ongoing research to further refine treatment protocols and improve patient outcomes. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Heart Fail Rev. 2025 Mar;30(2):271-286 | pt_PT |
| dc.identifier.doi | 10.1007/s10741-024-10461-3 | pt_PT |
| dc.identifier.eissn | 1573-7322 | |
| dc.identifier.issn | 1382-4147 | |
| dc.identifier.uri | http://hdl.handle.net/10400.5/98352 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Springer Nature | pt_PT |
| dc.relation.publisherversion | https://link.springer.com/journal/10741 | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | pt_PT |
| dc.subject | Chronic kidney disease | pt_PT |
| dc.subject | Heart failure | pt_PT |
| dc.subject | Hyperkalemia | pt_PT |
| dc.subject | Patiromer | pt_PT |
| dc.subject | RAASi therapy | pt_PT |
| dc.subject | Sodium zirconium cyclosilicate | pt_PT |
| dc.title | Hyperkalemia management: a multidisciplinary expert panel’s perspective on the role of new potassium binders | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 286 | pt_PT |
| oaire.citation.issue | 2 | pt_PT |
| oaire.citation.startPage | 271 | pt_PT |
| oaire.citation.title | Heart Failure Reviews | pt_PT |
| oaire.citation.volume | 30 | pt_PT |
| person.familyName | Garagarza | |
| person.familyName | Lopes | |
| person.givenName | Cristina | |
| person.givenName | José António | |
| person.identifier.ciencia-id | 2C19-6ADD-4846 | |
| person.identifier.ciencia-id | B61C-2464-6E57 | |
| person.identifier.orcid | 0000-0002-3333-4694 | |
| person.identifier.orcid | 0000-0001-5563-5132 | |
| person.identifier.scopus-author-id | 16203649600 | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isAuthorOfPublication | 2fa4b9b0-3ebe-44a3-89c1-efe1e544654d | |
| relation.isAuthorOfPublication | 7e4466a0-3f01-4249-9234-e64f524a8556 | |
| relation.isAuthorOfPublication.latestForDiscovery | 2fa4b9b0-3ebe-44a3-89c1-efe1e544654d |